Relay Therapeutics, Inc. RLAY Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Relay Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: Relay Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relay Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relay Therapeutics, Inc.'s accrued expenses?
- Relay Therapeutics, Inc. (RLAY) reported accrued expenses of $847K in Q1 2026.
- How has Relay Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Relay Therapeutics, Inc.'s accrued expenses decreased by 49.6% year-over-year, from $1.68M to $847K.
- What is the long-term trend for Relay Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s accrued expenses has grown at a -39.6% compound annual growth rate (CAGR), from $5.76M to $463K.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.